- Home
- LPTX vs SWZ Comparison
LPTX vs SWZ Comparison
Compare LPTX & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- SWZ
- Stock Information
- Founded
- LPTX 2011
- SWZ 1986
- Country
- LPTX United States
- SWZ United States
- Employees
- LPTX N/A
- SWZ N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- SWZ Finance Companies
- Sector
- LPTX Health Care
- SWZ Finance
- Exchange
- LPTX Nasdaq
- SWZ Nasdaq
- Market Cap
- LPTX 119.6M
- SWZ 98.3M
- IPO Year
- LPTX N/A
- SWZ N/A
- Fundamental
- Price
- LPTX $2.55
- SWZ $8.45
- Analyst Decision
- LPTX Strong Buy
- SWZ
- Analyst Count
- LPTX 3
- SWZ 0
- Target Price
- LPTX $7.50
- SWZ N/A
- AVG Volume (30 Days)
- LPTX 335.2K
- SWZ 14.2K
- Earning Date
- LPTX 11-13-2024
- SWZ 01-01-0001
- Dividend Yield
- LPTX N/A
- SWZ 6.59%
- EPS Growth
- LPTX N/A
- SWZ N/A
- EPS
- LPTX N/A
- SWZ N/A
- Revenue
- LPTX N/A
- SWZ N/A
- Revenue This Year
- LPTX N/A
- SWZ N/A
- Revenue Next Year
- LPTX N/A
- SWZ N/A
- P/E Ratio
- LPTX N/A
- SWZ N/A
- Revenue Growth
- LPTX N/A
- SWZ N/A
- 52 Week Low
- LPTX $1.68
- SWZ $7.12
- 52 Week High
- LPTX $4.79
- SWZ $8.57
- Technical
- Relative Strength Index (RSI)
- LPTX 37.35
- SWZ 75.18
- Support Level
- LPTX $2.88
- SWZ $7.58
- Resistance Level
- LPTX $3.27
- SWZ $8.47
- Average True Range (ATR)
- LPTX 0.28
- SWZ 0.09
- MACD
- LPTX -0.06
- SWZ 0.11
- Stochastic Oscillator
- LPTX 12.71
- SWZ 97.96
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, and retail.